1. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group.
- Author
-
Akyildiz A, Gultekin M, Yigit E, Demir E, Ismayilov R, Ahmed M, Buyukkor M, Yildirim HC, Yildirim N, Ucar G, Algin E, Ozturk AE, Akbas S, Selcukbiricik F, Orman S, Turan N, Yilmaz M, Colak R, Engin EO, Majidova N, Bayoglu IV, Beyaz H, Ates O, Ibıs K, Ergen SA, Yuce Sari S, Tezcan Y, Yildiz F, and Arik Z
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Adult, Aged, Turkey epidemiology, Antineoplastic Agents administration & dosage, Young Adult, Aged, 80 and over, Neoplasm Staging, Uterine Cervical Neoplasms therapy, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms drug therapy, Cisplatin administration & dosage, Chemoradiotherapy methods
- Abstract
Objective: To investigate the impact of cumulative cisplatin dose on clinical outcomes in locally advanced cervical cancer patients undergoing definitive chemoradiotherapy., Methods: A retrospective analysis was conducted on 654 patients with stage IB3-IVA disease treated with definitive chemoradiotherapy. Radiotherapy was applied as external beam pelvic with or without para-aortic radiotherapy and brachytherapy. Concomitant chemotherapy was in the form of weekly or 3 weekly cisplatin. Data on demographics, treatment protocols, cumulative cisplatin dose, adverse effects, and survival outcomes were collected. Statistical analyses, including univariate and multivariate Cox regression models, were used to assess factors influencing progression free survival and overall survival., Results: The median cumulative cisplatin dose was 210 mg (range 40-320), and ≥200 mg in 503 (76.9%) patients. Median follow-up was 35 months (range 1-150). The 5 year progression free survival and overall survival rates were 66.9% and 77.1%, respectively. Multivariate analysis identified poor performance status, non-squamous cell histology, presence of lymph node metastases, and hemoglobin <10 g/dL before chemoradiotherapy as poor prognostic factors for both progression free survival and overall survival in the whole group. When stage III cases were evaluated separately, the cumulative cisplatin dose <200 mg was found to be a significant poor prognostic factor in overall survival (hazard ratio 1.79, 95% confidence interval 1.1 to 3.0, p=0.031)., Conclusion: Our study showed that a cumulative cisplatin dose >200 mg, particularly in patients with lymph node metastases, significantly improved overall survival. Factors such as anemia, toxicity related challenges, and comorbidities were identified as critical considerations in treatment planning. These findings emphasize the balance between maximizing therapeutic efficacy and managing toxicity, guiding personalized treatment approaches for locally advanced cervical cancer., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF